bLAC - Treatment of Cutaneous Warts in Immune Suppressed, Kidney Transplanted Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2008
As many as 85 % of renal transplant patients may suffer from viral warts with a high degree of treatment resistance. Promising results of hLAC (human lactalbumin complex with lipid) point to a beneficial effect without noticeable side effects of bLAC (bovine lactalbumin complex with lipid). The aim of first clinical trial with bLAC is to show proof of concept in treatment of cutaneous wart lesions on hands and/or feet after local administration of bLAC in two dose groups to immune suppressed, kidney transplanted patients.
Epistemonikos ID: e0dcdfc62a1718bf181ae5f7334b0084881f1c7c
First added on: May 04, 2024